I
n the article by AbouEzzeddine et al "Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction," which published on February 18, 2017, and appeared in the February 2017 issue of the journal (J Am Heart Assoc. 2017;6:e004382. DOI: 10.1161/JAHA.116. 004382.), the authors mistakenly referred to the ST2 as Suppression of Tumorigenicity 2, an entirely unrelated gene. The gene that is commonly reported as being a biomarker that is upregulated in heart failure and other systemic inflammatory diseases (and that the authors intended to refer to in this manuscript) is the gene IL1RL1 (interleukin 1 receptor like 1). Ambiguously, this was originally also termed ST2; hence the error that has been commonly made in the literature. The article has been corrected and all reference to Suppression of Tumorigenicity 2 has been corrected to Soluble ST2.
The authors regret the error. The online version of the article has been updated and is available at http://jaha.ahajournals.org/content/6/ 2/e004382 J Am Heart Assoc. 2017;6:e002231. DOI: 10.1161/JAHA.117.002231.
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